Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Industry News

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

April 24, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Industry News

Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths

July 13, 2016

News Daily News

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Caitlin E. Cox

July 07, 2016

News Conference News EuroPCR 2015

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Caitlin E. Cox

May 22, 2015

News Daily News

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

May 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Jason Kahn

September 15, 2011

Advertisement

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

FDA’s First Take on New Paclitaxel Concerns in CLI

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Studies Provide Encouraging Results for DCB in Long SFA Lesions

ILLUMENATE First-in-Human Study: Novel Drug-Coated Balloon Yields Strong 2-Year Outcomes in SFA Lesions

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Drug-Eluting Balloon Continues to Show Positive Results in SFA, Popliteal Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content